Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy

Inclusion Criteria: * II-III NYHA functional class, under optimal medical therapy. * LVEF ≥ 20% and ≤ 45% by echocardiography, SPECT or left ventriculogram one month prior to enrollment. * Anterior wall thickness ≥ 8 mm by echocardiography or MRI one month prior to enrollment. * Idiopathic DCM diagnosis (having excluded CAD, valvular heart disease, cardiac toxic drugs, tachyarrhythmias, metabolic diseases, systemic diseases, infectious diseases) six months prior to enrollment. * Patients rejected for heart transplantation should have been discussed in the Heart Team at their respective centres, and a document stating the reason for exclusion will be kept in the medical record. * Able to exercise on a treadmill, MVO2 between ≥ 12 and ≤ 21 ml/Kg/min. * Hemodynamic stability (blood pressure \> 100/40 mmHg, heart rate \< 110 bpm and oxygen saturation \> 95%). * Negative pregnancy test in women. * Signed informed consent Exclusion Criteria: * Evidence of secondary dilated cardiomyopathy causes: CAD, valvular heart disease, cardiac toxic drugs, tachyarrhythmias, metabolic diseases, systemic diseases, infectious diseases, myocarditis or postpartum ventricular dysfunction. * Permanent atrial fibrillation. * Candidates for ICD or CRT devices. Patients with theses devices can be enrolled if the device has been implanted at least 6 months before inclusion, and only if no-response has been observed to CRT. * Candidates for heart transplantation if surgery is anticipated in the next 2 …